Stock Ratings / Health Care / PRTA / financials

KMDA (52) MNPR (31) BLSM (46) FTH (39) ⌘ Pro Terminal →

Prothena Corporation plc (PRTA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.88 -2.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Prothena Corporation plc (PRTA) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $455.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRTA)Realized 20D OHLCV Swing Band: ±11.4%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PRTA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $91.4M

FY24

Rev $135.2M

FY25

Rev $9.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$9.7M	52%	-80%	-$244.1M	-$163.6M	-45%
FY 2024	$135.2M	52%	-80%	-$122.3M	-$150.1M	-45%
FY 2023	$91.4M	52%	-80%	-$147.0M	-$133.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRTA)

✓Walkthrough of PRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.71%▼ DESCENDING CHANNEL

2026-10-30O $8.79H $8.90L $8.35C $8.88VOL 452.3K

RES: $9.65SUP: $7.71SMA50: $8.76SMA200: $9.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRTA Butterfly Map → + Track PRTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRTA)

Health Care Rank #995 of 1016 ⚔️ KMDA vs PRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRTA vs. KMDA, MNPR, BLSM, FTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prothena Corporation plc (PRTA) ranks #995 by composite RQD confidence (24/100, grade E) and #465 by equity capitalization ($455.9M). Within this direct 5-issuer industry benchmark cohort, PRTA leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. KMDA currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with PRTA at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRTA ACTIVE Prothena Corporation plc	E	24/100	—	—	-35.0%	-2.42%	$455.9M	Benchmark Subject
KMDA Kamada Ltd.	D+	52/100	—	—	—	-0.62%	$458.8M	/kmda-vs-prta →
MNPR Monopar Therapeutics Inc.	E	31/100	—	—	-17.4%	-2.02%	$482.7M	/mnpr-vs-prta →
BLSM BlossomHill Therapeutics Inc.	D	46/100	—	—	—	-7.59%	$483.4M	/blsm-vs-prta →
FTH Faeth Therapeutics Inc.	D-	39/100	—	—	-35.0%	-2.34%	$484.5M	/fth-vs-prta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001559053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prothena Corporation plc (PRTA) reported GAAP revenue of $9.7M (-92.8% vs. FY2024 revenue of $135.2M , and -89.4% cumulative change since FY2023) , GAAP net income of -$244.1M, operating cash flow of -$163.6M, and free cash flow of -$163.6M (-9.0% YoY). On the balance sheet, PRTA closed FY2025 with $326.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.7M	-$244.1M	-$163.6M	-$163.6M	$326.8M	—
FY2024 (FY)	2024-12-31	$135.2M	-$122.3M	-$150.1M	-$150.1M	$547.1M	—
FY2023 (FY)	2023-12-31	$91.4M	-$147.0M	-$133.9M	-$133.9M	—	—

3. PRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $8.88 (-2.42% 1D, market cap $455.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #995 in composite RQD confidence.

How does PRTA compare to KMDA and MNPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KMDA (Kamada Ltd.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $458.8M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, PRTA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRTA?

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRTA last traded at $8.88 (-2.42% on volume of 370,119 shares), positioning the stock +1.37% above its 50-day simple moving average ($8.76) and -3.90% below its 200-day simple moving average ($9.24). Across its 52-week range of $7.73 to $11.80, PRTA sits at the 28.3% percentile with a 14-day RSI of 48.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($7.87 to $9.89).